Department of Gynecology and Obstetrics, Rouen University Hospital, Rouen, France; Research Group 4308, "Spermatogenesis and Gamete Quality," IHU Rouen Normandy, IFRMP23, Reproductive Biology Laboratory, Rouen University Hospital, Rouen, France.
J Minim Invasive Gynecol. 2013 Sep-Oct;20(5):573-82. doi: 10.1016/j.jmig.2013.02.016. Epub 2013 Jun 10.
To assess recurrence and pregnancy rates in women with ovarian endometrioma treated via ablation using plasma energy.
Retrospective non-comparative pilot study including 55 patients treated during 28 months, with prospective recording of data (Canadian Task Force classification II-2).
Tertiary referral center.
Fifty-five consecutive women with pelvic endometriosis in whom ovarian endometriomas were managed solely via ablation using plasma energy. The minimum follow-up was 1 year.
Endometrioma ablation using plasma energy.
Information was obtained from the database of the North-West Inter Regional Female Cohort for Patients with Endometriosis, based on self-questionnaires completed before surgery, surgical and histologic data, and systematic recording of recurrences, pregnancy, and symptoms. Recurrences were assessed using pelvic ultrasound examination. Mean (SD) follow-up was 20.6 (7.2) months (range, 12-39 months). In 75% of patients, deep infiltrating endometriosis was treated, and 40% had colorectal involvement. Preoperative infertility was recorded in 42% of patients. The rate of postoperative recurrence was 10.9% for the entire series. Of 33 women who wished to conceive, 67% became pregnant, spontaneously in 59%. Time from surgery to the first pregnancy was 7.6 (4.3) months. After discontinuation of postoperative hormone therapy, the probability of not conceiving at 12 months was 0.36 (95% confidence interval, 0.19-0.53), and at 24 months was 0.27 (95% confidence interval, 0.12-0.44).
Recurrence and pregnancy rates are encouraging in that they seem comparable to the best reported results after endometrioma cystectomy. Plasma energy may have an important role in the management of ovarian endometrioma in women seeking to conceive. Patients most in need of surgical procedures that can spare ovarian parenchyma, such as those with bilateral endometriomas or a history of ovarian surgery, may particularly benefit from ablation using plasma energy.
评估使用等离子能进行消融术治疗卵巢子宫内膜异位症的患者的复发和妊娠率。
回顾性非对照性试点研究,纳入了 28 个月内治疗的 55 例患者,前瞻性记录数据(加拿大任务组分类 II-2)。
三级转诊中心。
55 例连续的盆腔子宫内膜异位症患者,仅通过等离子能消融术治疗卵巢子宫内膜异位症。最低随访时间为 1 年。
使用等离子能进行子宫内膜异位症消融术。
信息来自基于自我问卷的西北地区女性子宫内膜异位症患者区域队列数据库,该问卷在手术前完成,手术和组织学数据,以及复发、妊娠和症状的系统记录。复发情况通过盆腔超声检查评估。平均(SD)随访时间为 20.6(7.2)个月(范围,12-39 个月)。在 75%的患者中,深部浸润性子宫内膜异位症得到了治疗,40%有结直肠受累。42%的患者术前存在不孕。整个系列的术后复发率为 10.9%。在 33 名希望怀孕的患者中,67%自然怀孕,59%在术后。从手术到第一次怀孕的时间为 7.6(4.3)个月。停止术后激素治疗后,12 个月未怀孕的概率为 0.36(95%置信区间,0.19-0.53),24 个月未怀孕的概率为 0.27(95%置信区间,0.12-0.44)。
复发和妊娠率令人鼓舞,因为它们似乎与子宫内膜异位症囊肿切除术的最佳报道结果相当。等离子能在希望怀孕的女性的卵巢子宫内膜异位症管理中可能具有重要作用。最需要能够保留卵巢实质的手术的患者,例如双侧子宫内膜异位症或卵巢手术史的患者,可能特别受益于等离子能消融术。